Citius Oncology, Inc. (CTOR)

Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022
Net Income	-19.52	-12.7	-10.87
Stock-Based Compensation	7.8	1.97	-
Other Operating Activities	0.58	0.58	1.15
Change in Accounts Payable	-1.27	1.2	0.18
Change in Other Net Operating Assets	12.42	8.96	9.53
Levered Free Cash Flow	7.11	4.55	-
Unlevered Free Cash Flow	7.11	4.55	-
Change in Net Working Capital	-11.15	-10.16	-

Source: S&P Capital IQ. Standard template. Financial Sources.